Ibaraki, Japan

Noboru Yamamoto

USPTO Granted Patents = 11 


Average Co-Inventor Count = 8.9

ph-index = 6

Forward Citations = 231(Granted Patents)


Location History:

  • Ibaraki, JP (2002 - 2005)
  • Tsukuba, JP (2013)
  • London, GB (2012 - 2015)

Company Filing History:


Years Active: 2002-2015

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Noboru Yamamoto: Innovator in Neurodegenerative Disease Research

Introduction

Noboru Yamamoto is a prominent inventor based in Ibaraki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating neurodegenerative diseases. With a total of 11 patents to his name, his work has garnered attention for its potential therapeutic applications.

Latest Patents

Yamamoto's latest patents include innovative compounds known as fused aminodihydrothiazine derivatives. These compounds are represented by a general formula that includes various structural components, such as Caryl groups and Calkylene groups. They have been shown to possess Aβ production inhibitory effects and BACE1 inhibitory effects, making them useful as prophylactic or therapeutic agents for neurodegenerative diseases, particularly Alzheimer-type dementia.

Career Highlights

Throughout his career, Noboru Yamamoto has worked with notable companies in the pharmaceutical industry, including Eisai Company, Limited and Eisai R&D Management Co., Ltd. His research has focused on developing effective treatments for conditions that affect cognitive function and overall brain health.

Collaborations

Yamamoto has collaborated with esteemed colleagues in his field, including Yuichi Suzuki and Toshihiko Kaneko. These partnerships have contributed to the advancement of research and innovation in neurodegenerative disease therapies.

Conclusion

Noboru Yamamoto's contributions to the field of pharmaceuticals, particularly in the area of neurodegenerative diseases, highlight his role as an influential inventor. His innovative compounds and collaborative efforts continue to pave the way for potential breakthroughs in treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…